녹내장 수술 기기 시장 : 제품 유형, 적응증 유형, 재질 유형, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Glaucoma Surgery Devices Market is projected to grow by USD 1.65 billion at a CAGR of 7.40% by 2032.

Glaucoma Surgery Devices Market Introduction

Glaucoma surgery devices are moving from a specialist-only intervention category to a broader sight-preservation platform shaped by earlier diagnosis, longer life expectancy, and demand for safer intraocular pressure control. Glaucoma is a leading cause of irreversible blindness, and peer-reviewed epidemiology has projected the number of people with glaucoma to rise from about 76 million in 2020 to nearly 112 million by 2040.

The market is anchored by the clinical reality that lowering intraocular pressure remains the only proven modifiable strategy to slow glaucoma progression. This keeps trabeculectomy devices, glaucoma drainage implants, micro-invasive glaucoma surgery devices, canal-based systems, cyclophotocoagulation platforms, and combined cataract-glaucoma procedures central to ophthalmic surgical planning.

Transformative Shifts in the Glaucoma Surgery Device Landscape

The glaucoma surgery devices landscape is being reshaped by the shift from late-stage invasive surgery toward earlier, lower-trauma intervention. Micro-invasive glaucoma surgery has expanded the treatment continuum, particularly for mild-to-moderate open-angle glaucoma patients undergoing cataract surgery, while tube shunts and filtering procedures remain essential for advanced and refractory disease.

Regulatory rigor, surgeon training, real-world evidence, and reimbursement scrutiny are becoming decisive market forces. Hospitals and ambulatory surgery centers increasingly evaluate devices not only on pressure reduction, but also on safety profile, medication burden reduction, procedure time, durability, and fit with outpatient ophthalmology workflows.

Cumulative Impact of Artificial Intelligence on Glaucoma Surgery

Artificial intelligence is not replacing glaucoma surgeons, but it is changing the decision environment around glaucoma surgery devices. AI-enabled analysis of optical coherence tomography, optic nerve images, visual fields, and electronic health records can support earlier risk stratification and help identify patients likely to progress despite medication or laser therapy.

The cumulative impact is expected to be strongest in referral timing, surgical planning, post-operative monitoring, and outcomes analytics. AI can help manufacturers and providers generate real-world evidence on intraocular pressure reduction, complication rates, and medication reduction, but adoption depends on clinical validation, explainability, cybersecurity, and compliance with medical device software regulations.

Key Regional Insights Across Glaucoma Surgery Devices

Asia-Pacific represents the largest long-term volume opportunity because glaucoma burden is linked to population scale, aging demographics, and expanding ophthalmology capacity in China, India, Japan, South Korea, and Australia. Rising cataract surgery capacity, urban specialty eye hospitals, and public blindness-prevention programs are supporting wider procedural access, although affordability and trained glaucoma surgeon availability remain uneven across the region. North America remains a high-value innovation region, supported by FDA pathways, specialist glaucoma practices, ambulatory surgery centers, and strong adoption of premium cataract and glaucoma procedures.

Europe is shaped by CE marking, Medical Device Regulation requirements, and country-level health technology assessment, creating demand for strong clinical evidence, post-market surveillance, and payer-relevant outcome data. Latin America shows opportunity through Brazil and Mexico, where private ophthalmology networks and cataract surgery demand support adoption, although access and reimbursement vary widely. The Middle East, led by GCC investment in specialty hospitals and imported ophthalmic technologies, is modernizing glaucoma care, while Africa remains underpenetrated due to limited screening, surgical capacity, specialist distribution, and affordability constraints.

Key Group Insights for Glaucoma Surgery Device Adoption

ASEAN markets are characterized by uneven reimbursement and a growing private ophthalmology sector, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines offering different routes to adoption based on specialist density, hospital investment, and medical tourism. GCC countries favor advanced hospital infrastructure and imported specialty technologies, making clinical education, regulatory readiness, and distributor strength critical for glaucoma surgery device commercialization.

The European Union rewards evidence-backed devices that can meet MDR documentation, clinical evaluation, vigilance, and post-market surveillance expectations. BRICS countries combine high patient volumes with cost sensitivity and variable public procurement systems, making scalable device economics and local clinical training important. G7 markets lead in clinical research, reimbursement debates, and premium technology adoption, while NATO countries provide overlapping demand through resilient healthcare infrastructure, standardized quality expectations, and procurement standards across many advanced health systems.

Key Country Insights in Glaucoma Surgery Devices

The United States leads commercialization for many glaucoma surgery devices due to specialist density, FDA-recognized clinical evidence, ambulatory procedure capacity, and integration of glaucoma procedures with cataract surgery, while Canada emphasizes provincial reimbursement, health technology evaluation, and evidence-based adoption. Mexico and Brazil offer large patient pools with private-sector momentum and expanding ophthalmology services, but affordability, uneven insurance coverage, and public-sector access remain important.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced ophthalmology networks with strict evidence expectations, payer scrutiny, and growing interest in procedures that reduce medication burden. Russia faces more variable access, regional procurement complexity, and dependence on hospital-level investment. China and India represent major volume opportunities due to population scale, aging demographics, and expanding eye-care infrastructure; Japan and South Korea support high-quality device adoption through advanced ophthalmic practice and technology-oriented care pathways; and Australia benefits from organized specialist care, established cataract-glaucoma surgical pathways, and a well-developed private ophthalmology sector.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence that proves sustained intraocular pressure control, medication burden reduction, durability, and safety across diverse glaucoma severities. Device portfolios should align micro-invasive solutions with advanced disease technologies rather than treating them as competing categories, ensuring surgeons can match procedures to disease stage, anatomy, risk profile, and prior treatment history.

Manufacturers should strengthen surgeon education, post-market registries, payer dossiers, regulatory documentation, and partnerships with cataract surgery networks. Regional strategies should balance premium positioning in North America, Japan, Australia, and Western Europe with value-engineered access models in India, China, Latin America, ASEAN, Africa, and parts of the Middle East, supported by training programs and service infrastructure.

Research Methodology

This executive summary is built on a triangulated research approach using peer-reviewed glaucoma epidemiology, ophthalmology society guidance, regulatory intelligence, clinical trial evidence, reimbursement patterns, public health data, and regional healthcare infrastructure analysis. Insights are assessed against established clinical facts, including the central role of intraocular pressure reduction in slowing glaucoma progression.

The methodology evaluates device demand through segmentation by procedure type, care setting, geography, adoption barriers, regulatory pathways, and competitive positioning. It emphasizes validated public sources, expert interpretation, and cross-checking of clinical and commercial signals to avoid reliance on unverified claims, market sizing, or unsupported projections.

Conclusion

The glaucoma surgery devices market is positioned for sustained relevance as the global glaucoma burden rises and clinicians seek safer, earlier, and more durable pressure-lowering interventions. Micro-invasive glaucoma surgery is expanding access to procedural care for appropriate patients, while traditional filtration and drainage devices remain indispensable for severe, complex, and refractory disease.

Future performance will depend on evidence quality, surgeon confidence, reimbursement alignment, AI-enabled care pathways, regulatory compliance, and geographic access strategies. Organizations that combine clinical rigor with scalable commercialization and strong training support will be best positioned to advance glaucoma care and help protect vision worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Glaucoma Surgery Devices Market, by Product Type

• 7.1. Glaucoma Drainage Devices
  • 7.1.1. Valves
  • 7.1.2. Drainage Implants
  • 7.1.3. Stents
• 7.2. Minimally Invasive Glaucoma Surgery Devices
• 7.3. Laser Based Devices

8. Glaucoma Surgery Devices Market, by Indication Type

• 8.1. Open Angle Glaucoma
• 8.2. Closed Angle Glaucoma

9. Glaucoma Surgery Devices Market, by Material Type

• 9.1. Silicone Based Devices
• 9.2. Polypropylene Devices
• 9.3. Biodegradable Polymers

10. Glaucoma Surgery Devices Market, by End User

• 10.1. Ambulatory Surgery Centers
• 10.2. Hospitals
• 10.3. Ophthalmic Clinics
• 10.4. Academic Institutions

11. Glaucoma Surgery Devices Market, by Distribution Channel

• 11.1. Online Sales
• 11.2. Offline Sales

12. Glaucoma Surgery Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Glaucoma Surgery Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Glaucoma Surgery Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Alcon Inc.
• 16.3. Bausch & Lomb Incorporated
• 16.4. Carl Zeiss Meditec AG
• 16.5. Ellex Medical Lasers Ltd.
• 16.6. Glaukos Corporation
• 16.7. Implandata Ophthalmic Products GmbH
• 16.8. Iridex Corporation
• 16.9. iSTAR Medical SA
• 16.10. Johnson & Johnson Vision Care, Inc.
• 16.11. Lumenis Ltd.
• 16.12. Medicontur International Zrt.
• 16.13. MicroSurgical Technology, Inc.
• 16.14. New World Medical, Inc.
• 16.15. NIDEK Co., Ltd.
• 16.16. Santen Pharmaceutical Co., Ltd.
• 16.17. Sight Sciences, Inc.
• 16.18. STAAR Surgical Company